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Adnan Gopinadhan 
INVESTIGATING THE PRESENCE OF Pfkelch GENE 
MUTATIONS IN UGANDAN CHILDREN WITH SEVERE 
MALARIA 
 
Artemisinin resistance was first observed in Southeast Asia (SEA) and could pose a 
threat to malaria treatment all over the world. Recently mutations in the propeller 
region of Pfkelch13 gene have been used as a genetic marker for resistance observed 
in SEA. We investigated the presence of mutations in the Pfkelch gene in children in 
Kampala, Uganda with severe malaria (SM) treated with intravenous quinine, or 
with asymptomatic P.falciparum infection (AP) treated with artemether-
lumefantrine. We sequenced the Pfkelch gene (2178bp) in 157 children with SM and 
49 children with AP infection. In children with SM and AP we identified 106 (60.8%) 
and 27 (55.1%) parasites with mutations upstream of the Pfkelch13 propeller 
region. The two most prevalent mutations were 142NN (26.1% in SM, 33% in AP) 
and K189T (16.5% in SM, 12.2% in AP). In SM, only a single infection had a mutation 
in the propeller region (A578S), while in AP, mutations in the propeller region 
included A578S (n=1) and S522C (n=1). In children with SM, parasites with 142NN 
insertion compared to 3D7 Pfkelch13 parasites had lower parasite density (p=0.02) 
and lower parasite biomass (p=0.03). Children with SM who either had 142NN or 
K189T mutation cleared parasites after quinine treatment faster than those with the 
3D7 Pfkelch13 genotype (P<0.001 for both mutations compared to 3D7). In this 
cohort mutations, upstream of the Pfkelch13 propeller region were common. Future 
studies will assess the presence of Pfcrt and Pfmdr mutations in this cohort, and how 
these relate to the Pfkelch13 mutations and to parasite clearance.  
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INTRODUCTION 
 
1.1 A general overview 
Malaria is one of the major health concerns facing most of the developing world.  It 
is caused by an infection with a protozoan parasite of the genus Plasmodium. It was 
first identified in the blood smear of an Algerian patient in 1880 as the cause of 
malaria [7]. In 1897 while working in India, Ronald Ross identified plasmodial 
oocysts in the guts of mosquitoes, hence identifying mosquitoes as the vector of 
malaria [8]. Since the first half of the 20th century efforts to eliminate malaria have 
been on going. In 1955 the Global Malaria Eradication Program was launched by the 
World Health Organization (WHO) in all parts of the world except for Africa. This 
program involved residual spraying and systemic detection and treatment of cases. 
This program was later abandoned due to financial and technical issues. However, 
even with once highly effective drugs such as chloroquine and insecticides such as 
dichlorodiphenyltrichloroethane (DDT) human malaria still persisted. 
 
In 2015, there were 212 million new cases of malaria reported worldwide and 
Africa accounted for 90% of these cases [9]. In the same year there was an estimate 
of 429,000 malaria deaths worldwide and 92% of these occurred in Africa, followed 
by Southeast Asia (SEA) (6%) and the Eastern Mediterranean Region (2%) [9]. 
However, malaria case incidence has been dropping rapidly and between 2000 – 
2015, there was a 21% reduction globally [9]. During the same time period malaria 
related mortality rates fell by an estimated 29% globally and 31% in the African 
Region [9]. The reasons for the decline in malaria cases this century is due to 
increased interventions like insecticide treated bed nets (ITNs), indoor residual 
spraying of insecticides (IRS) and the use of newer effective drugs like artemisinin-
based combination therapies (ACTs) [9]. Yet malaria remains an important public 
health issue around the world (Figure 1.1) due to various factors like poverty, lack 
of adequate treatment policies around the world and also emergence of drug 
resistant strains. 
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Malaria related mortality is mainly associated with children under the age of 5 years 
[9]. An estimated 303,000 deaths of children under the age of 5 due to malaria of 
which 292,000 were from the African Region in 2015 [9]. Cerebral malaria is the 
main driver of malaria related mortality in children. 
 
 
 
 
 
 
1.2 Parasite life-cycle 
Human infections can be caused by five Plasmodium species: P. falciparum, P. vivax, 
P. malariae, P. ovale and P. knowlesi. The majority of the severe malaria cases are 
due to P. falciparum infections. The human infection begins when an infected female 
Anopheles mosquito injects P. falciparum sporozoites into the skin of an individual. 
Within minutes, these sporozoites travel to the liver and invade hepatocytes. It is 
here that the sporozoites initiate intracellular replication, which is known as the 
pre-erythrocytic development (10-12days). This is followed by the release of 
merozoites into the bloodstream, where they infect red blood cells (RBCs) and 
 
Source: World Health Organization[3] 
Figure 1.1 Percentage of world population at risk of malarial infections 
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initiate the asexual parasite multiplication stage. Upon invasion of the RBCs, the 
merozoites develop either through the sexual or asexual cycle. 
 
      
      
 
 
 
Under certain conditions that are not well understood a small number of infected 
red blood cells (iRBCs) commit to the sexual cycle and develop into gametocytes. 
These gametocytes can be picked up by another mosquito to restart the 
transmission cycle. Most of the merozoites commit to the asexual blood stage within 
the iRBC. This involves various stages from early ring stage to trophozoite and 
finally the schizont stage within 48 hours. At the end of the 48-hour cycle, the iRBCs 
burst to release merozoites into the circulation and infecting more RBCs (Figure 
Figure 1.2 Plasmodium falciparum life cycle 
Source: Robert Menard et al. 2013[5] 
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1.2). The rupture of the iRBCs is mainly responsible for the clinical symptoms like 
periodic waves of fever and anemia. 
 
1.3 Malaria pathogenesis 
Clinical symptoms of malaria are due to the infection of human red blood cells by 
parasite merozoites. The clinical symptoms of malaria generally result in 
uncomplicated or severe malaria. Uncomplicated malaria caused by P. falciparum 
generally begins with an irregular fever, which may occur daily with flu-like 
symptoms, diarrhea and anorexia. These patients are generally positive for 
parasites in their blood smear, but will not appear very ill. To the contrary, severe 
malaria is the main cause of fatal cases predominantly due to P. falciparum 
infections. Severe malarial anemia and cerebral malaria are the severe forms of the 
disease, however, there are other clinical manifestations that vary in the severity 
and outcome. These disease manifestations are associated with the parasite species 
and the treatment facilities available.  
 
P. falciparum infected erythrocytes are involved with a process called sequestration, 
where IEs adhere to the endothelial cells in the microvasculature of various organs. 
This results in impaired tissue perfusion, microcirculatory obstruction and 
activation of inflammatory cells resulting in severe disease. 
 
Rupture of iRBCs to release merozoites which further target erythrocytes and 
continue with the asexual life-cycle of the parasite. During this rupture, there are 
toxins and parasite products that further cause the activation of immune cells 
resulting in symptoms associated with a malarial infection.  
 
1.4 Severe Malaria 
Around 1-2% of the malarial infections lead to severe malaria [10] of which the 
mortality rate of in adults is 18.5% [11] and 9.7% in children [12]. The most 
common manifestations of severe malaria include cerebral malaria (CM), severe 
malarial anemia (SMA) and metabolic acidosis [10]. Severe malaria is observed in 
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adults in areas of low transmission, whereas in areas of stable transmission like 
many areas in Sub-Saharan Africa, tolerance to infection is observed in adults due to 
continuous exposure to infectious mosquitoes [13]. These adults have low levels of 
infection and are often asymptomatic [14]. However, children below the age of five 
living in high transmission areas are susceptible to developing severe malaria due to 
the lack of a sufficient immune response which is developed over multiple malaria 
infections and necessary for an effective response by the acquired immune system 
[15]. 
 
Cerebral Malaria 
The World Health Organization (WHO) defines CM as impaired consciousness upon 
P. falciparum infection with the absence of any other cause of coma. CM is graded 
based on two clinical scores a Blantyre coma score (BCS) and a Glasgow come score 
(GCS). BCS and GCS consist of 3 categories: eye movement, verbal response and 
motor response. BCS uses a scale of 0-2, where 0 being the least responsive while 
GCS uses a scale of 1-6, where 1 is the least responsive for each of the categories. A 
BCS of less than 3 is used to determine impaired consciousness in children under 
the age of 5 and GCS of less than 11 in children older than 5 years of age [16]. In our 
study the definition of CM is restricted to children who remain unconscious at least 
one hour after convulsions and after receiving a bolus of glucose; this is to avoid 
enrolling children with hypoglycemia or febrile convulsions. We also perform Gram 
stain and cultures of cerebrospinal fluid (CSF) to rule out bacterial meningitis as the 
cause of coma. 
 
Nearly 9% of malarial admissions in Africa are associated with CM [17]. African 
children who survived an episode of CM often had long-term cognitive deficits 
(approximately 21%) [18]. Children with a larger number of seizures before 
admission and with longer coma duration and cognitive deficits [18]. The exact 
biological mechanisms underlying the cognitive deficits are still not clearly 
understood, however it is hypothesized that parasite sequestration in the cerebral 
microvasculature causes decreased blood flow resulting in increased hemorrhage. 
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This is one of the main factors in pathogenesis and resulting changes in the 
surrounding tissue, which may explain the neural dysfunction [19]. High levels of 
cytokines and chemokines also lead to exaggerated inflammation may also 
contribute to the severity of the disease [19]. Currently, no adjunctive treatment for 
CM in humans has decreased mortality or neurologic complications [20] and 
patients who are identified with CM are treated with intravenous antimalarials to 
reduce the parasite burden as quickly as possible. 
 
Severe Malarial Anemia 
The WHO defines SMA as having detectable levels of P. falciparum in peripheral 
blood and hemoglobin levels ≤ 5g/dL [16], while normal hemoglobin levels in 
children ranges from 11-13g/dL. In African children severe malaria is generally 
associated not only with malaria, but also HIV-1 infection, hookworm infections, 
vitamin deficiencies [21]. 
 
In Sub-Saharan Africa, SMA poses a substantial burden causing approximately 20% 
of P. falciparum related hospitalizations [17]. SMA related mortality is lower in an 
urban setting like Kampala, Uganda where access to good medical facilities is easier. 
Children who received adequate medical attention with severe anemia showed a 
lower mortality rate as compared to those who did not [22]. Adjunctive treatments 
for SMA have been limited, as rapid blood transfusion in combination with 
antimalarials usually reverses the severe anemia episode and reduces mortality. 
Associated symptoms like lactic acidosis and hypoxia are treated whenever 
presented by SMA patients [16]. 
 
1.5 Treatment 
Efforts to treat malarial infections have always had hurdles, in part due to the 
development and spread of drug resistant strains of P. falciparum. This species of 
parasites has developed some level of resistance against almost every antimalarial 
treatment regimen introduced to date (Figure 1.3) [6]. Drugs like chloroquine and 
sulfadoxine-pyrimethamine, which were initially used as a first line treatment of P. 
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falciparum malaria, have now been rendered ineffective in most malaria-endemic 
areas due to the emergence of resistant strains against these drugs [23]. 
 
 
Quinine 
Quinine has been the primary drug used in the treatment of malaria since the 
introduction of chinchona bark to European medicine in the 1630s. In the early 
1800s, the chinchona bark was dried and ground to a powder and mixed into a 
liquid, before the patient consumed it. In 1820, quinine was extracted from the bark 
and this purified quinine was used to treat malaria. Quinine is rapidly absorbed 
when consumed orally or through intravenous infusions, within 1-3 hours [24]. The 
half-life of quinine is approximately 11 hours [25], however, there are variations 
based on the age of the subjects and type of malaria. Quinine was the main drug 
used to treat malaria until the 1920s, when more effective synthetic drugs like 
chloroquine became readily available and were extensively used in the 1940s [26]. 
 
However, quinine was the most reliable drug used to treat severe malarial cases 
until recently; however, it is being replaced by artemisinin combination therapies 
(ACTs). With quinine treatment reports indicated there was a decrease in coma 
recovery times in severe malaria cases; however, there was no rise in mortality 
rates [27]. Hence quinine was still considered the best drug for treatment of severe 
malaria. Hospital treatment with quinine involves parenteral quinine administration 
through intramuscular injection or a slow rate-controlled intravenous infusion [28]. 
Drawbacks to the use of parenteral quinine treatment include pain at the site of 
intramuscular injection and an increased risk of developing lethal tetanus [29]. 
Quinine treatment also resulted in side effects such as hypoglycemia in children 
[30].  
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Chloroquine 
In the beginning of the 20th century, there was a demand for an alternate drug to 
quinine for the treatment of malaria. This led to development of one of the most 
important synthetic drug called chloroquine in 1934 [31]. Chloroquine proved to be 
one of the most effective drugs ever deployed against an infectious disease [32]. It 
was used for both treatment and prophylaxis. It is a potent schizonticide, effective 
against the asexual blood stage of all strains of Plasmodia [33]. 
 
 
 
 
 
 
Figure 1.3 Emergence of resistance to antimalarial drugs 
Colored bars represent an antimalarial montherapy or combination Years to the 
left of the bars represent when the drug was introduced and the first reported 
instance of resistance. The ovals below the time line denote the approximate 
periods when resistance spread through the different regions in the world. ACTs: 
Artemisinin based Combination Therapies, AQ, amodiaquine; Ato/Pg: 
Atovaquine/Proguanil, CQ: Chloroquine, Halo: Halofantrine, MQ, mefloquine; Q: 
Quinine, R:Resistance, S/P: Sulfadoxine/Pyrimethamine. 
 
Source: Eric . Ekland and David A. Fidock, 2018 [6] 
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Artemisinin 
In 2005, the WHO began recommending the use of ACTs (artemisinin combination 
therapy) as the first line of treatment for P. falciparum infections. This involves the 
use of an artemisinin derivative (artesunate or artemther), which is highly potent 
and short-lived along with a long-acting antimalarial such as lumefantrine, 
mefloquine or amodiquine. Treatment using ACTs have dramatically reduced 
malaria burden in the world [9] and has reduced mortality and morbidity associated 
with malaria [34-36]. Currently, cases of severe malaria are also being treated with 
ACTs due to the reduced rate of mortality compared to quinine treatment [11, 12]. 
 
Artemisinin was discovered in 1971, which initiated a new age of antimalarial drug 
therapy. It was isolated from the Chinese medicinal herb Artemisia annua. Later in 
1979, the crystal structure was determined to show the presence of a peroxide 
bridge. The exact mechanism of artemisinin action is not known and is an active 
area of research, however, it is hypothesized that this peroxide bride is responsible 
for the drug action [37]. It is highly insoluble in oil and water and hence is 
administered orally. 
 
There are semisynthetic derivatives/analogs of artemesinin such as 
dihydroartemisinin (DHA), artesunate, artemether and arteether, which are all 
regarded as potent drugs against malaria. The derivatives can be administered to 
patients via intramuscular injection. They are fast acting and have a short half-life of 
around 1-5 hours depending on the type of derivative. Regardless of the specific 
type of artemesinin or derivative administered, all these compounds are 
metabolized into DHA. 
 
However, in 2009, a study conducted in SEA demonstrated slow parasite clearance 
times in individuals treated with artemisinin monotherapy and ACTs. The observed 
delayed parasite clearance times in vivo was termed artemisinin resistance [38, 39]. 
The spread of artemisinin-resistant (delayed clearance) P. falciparum to 
surrounding regions is now threatening the world’s malaria control and elimination 
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efforts [40]. Spread of resistant strains from Cambodia to Greater Mekong Subregion 
and to Africa has happened before with chloroquine and sulphadoxine-
pyrimethamine [41, 42]. 
 
1.6 Malaria drug resistance 
Antimalarial drugs have been key to malaria control especially due to the lack of an 
effective vaccine against malarial infections. As mentioned earlier (1.5) there have 
been various drugs used in the treatment of malaria, however, resistance to these 
drugs have been a major concern throughout history (Figure 1.3).  
 
Quinine resistance 
Resistance to quinine was first reported in Brazil and later in SEA [27, 43]. Quinine 
resistance is associated with polymorphisms in several transporters. 
Polymorphisms associated with pfmdr1, pfcrt are linked to decreased quinine 
sensitivity. In addition increase in pfmdr1 copy number can also lead to quinine 
resistance [44]. 
 
Chloroquine resistance 
Due to the high availability and widespread use of chloroquine, there were cases of 
resistance being reported in the late 1950s at the Cambodia-Thailand border [45] 
and in the 1980s it had spread to all areas with P. falciparum malaria. As a result 
quinine remained and continued to be the drug used in the treatment of severe 
malaria. 
 
In Africa, spread of chloroquine resistant strains became a major health problem 
and drug policies and formulation shifted to the use of combination therapy. This is 
when two or more drugs are administered simultaneously to a patient. This has a 
dual effect, as it can improve the efficiency of the treatment due to the different half-
lives of these drugs and at the same time reduce the chances of developing resistant 
strains [46-48].  
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Artemisinin resistance (Delayed Clearance) 
The emergence of artemisinin resistance in SEA resulted in efforts to find the 
molecular markers associated with this phenomenon. A study conducted in 2014 
used an artemisinin-resistant laboratory adapted strain and performed whole 
genome sequencing to compare the genome of this strain with the clinical strains 
from Cambodia. They identified non-synonymous single nucleotide polymorphism 
(SNP) within the kelch propeller region of the PF3D7_1343700 locus (Pfkelch-
13)(Figure 1.4) [49]. 
 
 
 
 
 
Since the identification of PF3D7_1343700 as molecular marker for artemisinin 
resistance, there have been several studies across regions in the world aimed at 
finding all the possible SNPs that can be associated with delayed parasite clearance 
times [50]. Only non-synonymous SNPs in the propeller region of the Pfkelch-13 
gene have been associated with delayed clearance [50] based on the parasite 
clearance half-life. The most common SNPs in the propeller region of the Pfkelch-13 
isolated from SEA: Cysteine 580 Tyrosine (C580Y), Arginine 539 Threonine 
(R539T), Tyrosine 493 Histidine (Y493H) and Isoleucine 543 Threonine (I543T) 
[49]. 
 
Figure 1.4 P. falciparum kelch13 protein sequence  
 
Consists of Plasmodium specific sequences, a bric-a-brac tramtrack, broad-complex 
domain and six kelch domains which are predicted to form a blade propeller structure 
which could be involved in protein-protein interaction.  
Source: Adapted from Rick M. Fairhurst [4] 
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Alternatively, recent studies using culture adapted clinical isolates from SEA have 
identified parasites with increased ring-stage survival times in the absence of 
mutations in the propeller domain of the Pfkelch13 gene [51].  
 
The mutant strains were mainly associated with regions in SEA, and were not 
observed in Africa, however a study conducted in children with severe malaria in 
Uganda, Africa found the presence of an alanine residue at position 578 replaced by 
a serine (A578S) mutation at low frequency was associated with delayed parasite 
clearance (>72hr) time upon ACT treatment [52]. Since this initial observation, 
there have been many studies conducted in Africa, to determine whether the 
presence of mutant parasites is increasing and spreading, as this might result in a 
major public health crisis in Africa [52-55]. 
 
1.7 Mechanism of artemisinin resistance 
 
We do not have a complete understanding about the mechanism involved in 
artemisinin resistance.  There are a few proposed mechanisms: 
1) A transcriptomics study of isolates from patients in SEA with malaria 
parasites with delayed parasite clearance times in response to artemisinin 
treatment had an increase in the ‘unfolded protein response’ pathway [56]. 
This could be a mechanism by which the parasite survives artemsinin action, 
by repairing the damaged proteins. Hence further studies into the cell stress 
response might give a better understanding of the role played by the stress 
response during artemisinin exposure. 
2) Another study provided evidence that artemisinin targets the P. falciparum 
phosphatidylinositol-3-kinase (PfPI3K) and that PfPI3K binds to PfKelch13 
[2]. In case of artemisinin-sensitive strains, PfKelch13 binds to PfPI3K and 
this cause PfPI3K to undergo polyubiquitination resulting in its proteosomal 
degradation. These sensitive parasites have low levels of P. falciparum 
phosphatidylinositol-3-phosphate (PfPI3P), which is a product of PfPI3K 
activity (Figure 1.5) [2]. 
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Artemisinin resistant strains containing polymorphisms in PfKelch13 are unable to 
bind to PfPI3K, leading to an increase in the PfPI3K levels. Increased concentrations 
of PI3P are hypothesized to enable parasite survival during artemisinin drug 
pressure (Figure 1.6) [2]. 
 
 
Figure 1.5 Artemisinin sensitive strain 
Artemisinin is activated in the presence of free heme. This results in the 
degradation of PfPI3K. Degradation of PfPI3K results in the reduced levels 
of PI3P, which is reported to be involved with transport of proteins from 
the parasite to the host cell [1]. This results in parasite death. 
Source: Adapted from Mbengue et al [2] 
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Figure 1.6 Artemisinin resistant strain 
Activation of artemisinin results in the degradation of PfPI3K. However, 
due to kelch propeller mutations the levels of PfPI3K are much higher as 
compared to the sensitive strain, hence even though there is degradation 
of PfPI3K, the levels of PI3P are able to prevent parasite death. 
Source: Adapted from Mbengue et al [2] 
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1.8 Research objectives: 
Studies conducted in SEA have reported resistance to most of the drugs used to treat 
malarial infections. SEA is a region of intermediate malaria transmission as a result 
of which individuals in this region have lower parasite burden. Artemisinin has been 
used to treat patients with uncomplicated malaria [57-60]. Resistant strains of the 
parasite to artemisinin treatment have also mainly been observed in SEA. These 
studies have identified mutations in the propeller domain of the Pfekelch13 gene 
associated with delayed parasite clearance times. In the past, resistance to malarial 
drug treatment have developed in SEA and gradually spread across to Sub-Saharan 
Africa. 
 
In our study conducted in Uganda between 2008 and 2013 children with severe 
malaria were treated with intravenous quinine. However, in 2005 there was a 
change in the treatment policy in Uganda towards the use of ACTs for 
uncomplicated malaria [61, 62]. Here we were interested in investigating the 
presence of parasites with mutations in the Pfkelch13 gene in our study population. 
In addition, a study conducted between 2011 and 2013 in Uganda by our group 
found a mutation (A578S) in the Pfkelch13 gene was associated with delayed 
parasite clearance in children with severe malaria who were treated with 
artemisinin [52]. This was the first time evidence of delayed parasite clearance time 
was documented in Sub-Saharan Africa and in a population with severe malaria 
(high parasite burden), rather than uncomplicated malaria. 
 
In the current study we investigate: 
 
1. The presence of mutations in the Pfkelch13 gene in children with severe 
malaria in Uganda, with high parasite burden. Our goal was to detect whether the 
A578S mutation was seen in a population that, unlike the original study population 
in which we found the A578S mutation, were not being treated with artesunate for 
severe malaria, but were being treated with ACTs for uncomplicated malaria.  
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2. Whether Pfkelch13 mutations, including the A578S mutation, are associated 
with changes in parasite clearance times in children treated with quinine. The use of 
ACTs outside this study group could also have an impact on the prevalence of these 
mutations. However, there is no known reason why these should affect parasite 
clearance times in children treated with quinine. In this study, we assess whether 
there is any association, with the idea that if an association with delayed clearance is 
seen, it may reflect mechanisms by which these mutations also affect quinine 
treatment effects on parasite clearance, or that these mutations are in linkage 
disequilibrium with other mutations that lead to delayed parasite clearance with 
quinine, or could reflect an association of the mutations with other factors such as 
impaired immunity that might affect parasite clearance. The long-term goal of this 
preliminary study is to determine whether mutations in the Pfkelch13 gene are 
present in other areas of Uganda and whether any mutations seen have effects on 
parasite clearance with a non-artemisinin containing intervention (quinine). 
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METHODS AND MATERIAL 
 
2.1 Study description 
 
Study area location 
The CMR01 study was conducted at Mulago National Referral and Teaching Hospital 
in Kampala, Uganda.  Uganda is a landlocked country in East Africa. It is bordered by 
Kenya to the east, Tanzania to the south, Democratic Republic of the Congo to the 
west, Rwanda to the southwest and South Sudan to the north.  In 2015, Uganda had 
a population of 39,032,000, with a per capita income of $1 based in 2013 record 
[63]. 
 
According to data from 2015, Uganda is an area of high transmission with more than 
1 case of malaria per 1000 individuals in a population. There were 7,137,662 (range 
4,500,000 – 13,000,000) reported cases of malaria, with nearly all of them being 
attributable to P. falciparum [63]. During the same period there were 6,100 cases of 
reported deaths with estimates of 4,300 – 17,000 [63]. 
 
2.2 Main study design 
 
Ethics Statement 
The Ugandan National Council for Science and Technology (UNCST), The Makerere 
University School of Medicine Research and Ethics Committee and the University of 
Minnesota Institutional Review Board approved this study. Written informed 
consent was obtained from the parents or guardians of the participants enrolled in 
the local language.  
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Selection of individuals  
The study was conducted between 2008-2013 and children were enrolled into three 
groups cerebral malaria (CM, n=269), severe malarial anemia (SMA, n=232) and 
community children (CC, n=213). The enrolled children were between the ages of 18 
months and 12 years and if they met the WHO definition for CM or SMA, were 
recruited from the Acute Care Unit at Mulago Hospital.  
 
Cerebral malaria was defined when a child was diagnosed with: 1) coma (Blantyre 
Come Score  2); 2) presence of P. falciparum infection on a blood smear; 3) no 
response to a glucose one hour after administration if hypoglycemic; 4) in a state of 
coma at least one hour after termination of seizure or after administration of 
anticonvulsants. Exclusion criteria for CM included: 1) white blood cell count > 5 
cells/μl in cerebral spinal fluid (CSF); 2) presence of bacterial infections by Gram 
stain and/or culture positive for CSF. For children suspected with CM a lumbar 
puncture (LP) was performed to rule out bacterial meningitis, unless the physician 
on duty deemed it unsafe or the parents or guardians of the child did not agree to 
have an LP performed.  
 
Severe malarial anemia was defined as: 1) presence of P. falciparum on a blood 
smear; 2) levels of serum hemoglobin was  5g/dl. Exclusion criteria in SMA 
included: 1) the children had any signs of impaired consciousness during the 
physical exam (GCS<15 for children older than 5 years of age and BCS <5 for 
children  5 years of age; 2) had seizures prior to admission. Some children 
presented both CM and SMA (22% of CM); these children were enrolled into the CM 
group.  
 
Community children were enrolled into the study from the neighborhood or 
extended family of a child with CM. These children were also between the age of 18 
months to 12 years of age and currently healthy. The community children were 
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excluded if they had any active illness or had an illness in the past 4 weeks requiring 
medical care. At the time of enrollment, a blood smear was prepared for the 
community children, and those with P. falciparum on the smear were sent home 
with antimalarials. These children were indicated as asymptomatic parasitemic 
(AP). 
 
Other exclusion factors for all children included: 1) any known chronic illness 
requiring medical care; 2) any developmental delay; 3) prior history of head trauma, 
coma, cerebral palsy, or hospitalization due to malnutrition.  
 
The children enrolled in this study were followed up for 2 years, and were asked to 
return to Mulago hospital in the event of any illness. Over this span of time 14 
children were admitted with CM, 26 were admitted with SMA, and 3 CC were 
admitted to the hospital. 
 
Clinical treatment 
The children enrolled in this study underwent a medical history and physical 
examination. Children with severe malaria were treated based on the Ugandan 
Ministry of Health treatment guidelines at the time, which involved intravenous 
quinine treatment until the patient is alert and then oral quinine for hospitalized 
patients; and artemisinin combination therapy, usually with artemether-
lumefantrine for outpatients. Currently there is no recommended adjunctive 
treatment for severe malaria; therefore, these children were provided supportive 
and symptomatic care, as needed, which mainly included anticonvulsants for CM. 
Children with SMA received a blood transfusion. The blood units provided to the 
hospitals in Uganda were screened as negative for HIV-1, syphilis, hepatitis B and 
hepatitis C [64]. 
 
Standard laboratory and clinical testing 
A complete blood count (CBC) was performed on all the enrolled children using a 
COULTER Ac . TTM 5diff CP (Cap Pierce) hematology analyzer. Immediately upon 
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enrollment the lactate, blood glucose and hemoglobin levels were also evaluated 
using hand held devices (lactate monitor, glucometer and hemo control). Only upon 
consent from the parents or guardians were the results included in the study. HIV-1 
testing was also performed upon consent from the parents or guardians. Three 
immunochromatographic tests (Determine, STAT-PAK and Uni-Gold) tests were 
performed and the dignosis was based on the Uganda National HIV testing 
algorithm. Stool samples from the enrolled children were examined by microscopy 
for the presence of motile trophozoites, helminthic ova or larva, red blood cells, 
protozoan cysts.  
 
Thick and thin blood smears were made to look for malaria parasites, this was done 
according to a standard protocol [65]. Fresh blood smears were prepared and 
checked for parasites by microscopy every 24 hours after intravenous quinine 
treatment. The parasite clearance times were calculated based on the absence of 
parasite in the blood smear after treatment. Parasite density was calculated using 
microscopy, however, this only provides an estimate of the circulating parasites in 
the blood. In the case of P. falciparum infection, infected red blood cells can 
sequester in the blood microvasculature of various organs, we also measured the 
levels of P. falciparum histidine rich protein-2 (PfHrp-2), which is a marker of 
overall parasite biomass. This parasite protein is released upon rupture of infected 
red blood cells at the end of the 48-hour asexual cycle. We quantified the levels of 
Hrp-2 using the Malaria Ag CELISA (Cellabs, Brookvale, Australia) and this provided 
an estimate of the sequestered parasite biomass [66]  
 
Specimen collection and storage 
Upon enrollment and at 6-month and 12-month follow up visits blood samples were 
collected in EDTA tubes. Plasma was prepared from whole blood tubes and was 
made into aliquots of 1 – 1.5 ml and stored at -80 °C. For patients diagnosed with 
severe malaria, blood was again collected at 24 hours and stored at -80 °C. Dried 
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blood spots were collected from all the patients upon enrollment, 6-month and 12-
month follow ups, which were stored at 4°C. 
 
2.3 Sample processing and DNA extraction 
Samples were collected during the main study (section 2.2) from Uganda. The work 
here utilized dried blood spots from children at enrollment as shown in a schematic 
diagram (Figure 2.1). We selected 50 children each from CM and SMA groups having 
high parasite burden (PfHrp2 levels) and 50 children with low parasite biomass 
from each CM and SMA groups.  
The rationale behind this was: 
• De novo mutations might occur during the asexual stage of the parasite life 
cycle. This increases the probability of more than one resistant parasite in an 
infection upon drug treatment in individuals with high parasite burden. 
Hence we looked at children with high parasite burden.  
• Resistance (delayed parasite clearance) to ACTs was first observed in 
patients treated for uncomplicated malaria in SEA. These patients had low 
parasite burden, however, there was selection of resistant strains in this 
population. Hence we also looked at children with lower parasite burden. 
 
Genomic DNA at enrollment was isolated from dried blood spots (Whatman 903 
Protein Saver Card, Cardiff, UK) for children with CM, SMA and CC using the QIAamp 
96 DNA Blood Kit (Qiagen, Hilden, Germany). 
However, Pfkelch13 genotyping was performed in only 78 (CM), 79 (SMA) and 49 
(CC) samples in each of these groups. We were unable to amplify 18 (CM), 15 (SMA) 
and 26 (CC) samples as DNA isolated from dried blood spots had very low genomic 
DNA concentrations and also low quality DNA (Table 2.1, Table 2.2 and Table 2.3). 4 
samples from CM and 6 samples from SMA group were ineligible for this study.   
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2.4 PCR amplification of Pfkelch13.  
Amplification of the Pfkelch13 gene was performed using a nested PCR protocol[49]. 
A diagrammatic representation is shown in (Figure 2.2).  
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Figure 2.1 Schematic representation of the current study design 
18 Samples in CM had low quality DNA. 4 Samples were ineligible 
15 Samples in SMA had low quality DNA. 6 Samples were inelgible 
Abbreviations: CM, Cerebral Malaria; SMA, Severe Malarial Anemia; CC, Community 
Control; Hrp2, Histidine Rich Protein 2 
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Table 2.1 Differences between the children with cerebral malaria (CM) that were tested 
and not tested 
 Tested (n =78) Not Tested (n =18) Pa 
 
P. falciparum peripheral blood 
density (parasites/μl), median 
(IQR) 
 
53680 (16200 – 279240) 
(n =75) 
 
38880 (26320 – 125900) 
(n =17) 
 
 
0.9719 
 
Total Parasite Biomass 
(PfHrp2)(ng/ml), Median (IQR) 
 
1825.2 (309.6 – 7486.5) 
 
7126.3 (470.4 – 12502.7) 
 
0.2867 
 
No. of Sample with High 
Parasite Biomass, (%) 
 
39 (78) 
 
10 (20) 
 
NA 
 
No. of Sample with Low 
Parasite Biomass, (%) 
 
39 (78) 
 
8 (16) 
 
NA 
a  Due to non-normality Wilcoxon Rank-Sum Test was performed 
Abbreviations: PfHrp2 (Plasmodium falciparum Histidine Rich Protein -2); IQR (Interquartile 
Range); n (Number); NA (Not Applicable) 
4 children were ineligible from this group 
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Table 2.2 Differences between the children with severe malarial anemia (SMA) that were 
tested and not tested 
 Tested (n =79) Not Tested (n =15) Pa 
 
P. falciparum peripheral 
blood density (parasites/μl), 
median (IQR) 
 
36820 (4360 – 117880) 
 
14120 (7820 – 35180) 
 
0.2116 
 
Total Parasite Biomass 
(PfHrp2)(ng/ml), Median 
(IQR) 
 
2469.6  (140.0 – 3725.7) 
(n =78) 
 
3051.5 (264 – 5929) 
(n =14) 
 
0.5755 
 
No. of Sample with High 
Parasite Biomass, (%) 
 
42 (84) 
 
8 (16) 
 
NA 
 
No. of Sample with Low 
Parasite Biomass, (%) 
 
37 (74) 
 
7 (14) 
 
NA 
a  Due to non-normality Wilcoxon Rank-Sum Test was performed 
Abbreviations: PfHrp2 (Plasmodium falciparum Histidine Rich Protein -2); IQR (Interquartile 
Range); n (Number); NA (Not Applicable) 
6 children were ineligible from this group 
 
 
Table 2.3 Differences between the children with asymptomatic infection (CC) that were 
tested and not tested 
 Tested (n =49) Not Tested (n =26) Pa 
 
P. falciparum peripheral blood 
density (parasites/μl), median 
(IQR) 
 
0 (0 – 1240) 
(n =48) 
 
0 (0 – 330) 
(n =24) 
 
0.1333 
 
Total Parasite Biomass 
(PfHrp2)(ng/ml), Median 
(IQR) 
 
4.8 (4.8 – 73.2) 
(n =44) 
 
4.8 (4.8 – 4.8) 
(n =24) 
 
0.2695 
a  Due to non-normality Wilcoxon Rank-Sum Test was performed 
Abbreviations: PfHrp2 (Plasmodium falciparum Histidine Rich Protein -2); IQR (Interquartile 
Range); n (Number) 
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          Figure 2.2 Diagrammatic representation of the Pfkelch13 gene 
   P. falciparum 3D7 strain showing both the primary and the secondary PCR  
   primers along with the size of the PCR product. 
 
 
A list of primers used for the primary amplification and secondary reaction is shown 
in table 2.4 and table 2.6. A total volume of 25μl reaction mixture was set for each 
primary PCR reactions in the PCR tubes. The reaction mixture was composed of 5X 
Phusion HF Buffer (5μl) supplied by (Thermo Scientific, USA), 5μM of forward and 
reverse primers (1μl each) supplied by (Eurofins Genomics, USA), 25mM dNTP 
(1.0μl) supplied by (Clontech, USA), 3mM MgCl2 (1.0μl) supplied by (Thermo 
Scientific, USA) and 2U/μl Phusion polymerase (0.5μl) supplied by (Thermo 
Scientific, USA). 5μl of genomic DNA was added into each reaction mixture and 
10.5μl of distilled water was used to make the volume up to 25μl. The cycling 
conditions used for the primary PCR amplification is shown in table 2.5. 
 
Table 2.4 List of primers used for the primary PCR amplification of Pfkelch13 gene 
 
Oligonucleotide Sequence 5’ – 3’ Tm (°C) 
KelchForwardN-1 
(Forward Primer) 
ATGGAAGGAGAAAAAGTAAAAACAAAAG 58.8 
KelchReverseN-1 
(Reverse Primer) 
TATATTTGCTATTAAAACGGAGTGACC 60.0 
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Table 2.5 Primary PCR amplification cycling conditions for the Pfkelch13 gene 
 
Gene Denaturing 
Temperature 
Annealing 
Temperature 
Extension 
Temperature 
Pfkelch13 94°C for 30 seconds 60°C for 90 seconds 72°C for 90 seconds 
 
 
The secondary PCR reaction for the Pfkelch13 gene was performed using a total 
volume of 25μl of reaction mixture in each PCR tube. The mix contained 1μl of 
primary PCR product, 10X PCR buffer (Mg+) (3.2μl) supplied by Clontech, USA, 2mM 
dNTP mixture (2.5μl), 5μM of forward and reverse primers (1.25μl each) supplied 
by (Eurofins Genomics, USA) as shown in table 2.6 and 5U/μl Takara Ex Taq® Hot 
Start Version supplied by (Clontech, USA). The cycling conditions used in the 
secondary PCR reactions are shown in table 2.7. 
 
Table 2.6 List of primers used in the secondary PCR reaction of the Pfkelch13 gene  
 
Oligonucleotide Sequence 5’ – 3’ Tm (°C) 
K13 – 1  
(Forward Primer) 
GGGAATCTGGTGGTAACAGC 62.4 
K13 – 4  
(Reverse Primer) 
CGGAGTGACCAAATCTGGGA 
 
62.4 
 
 
Table 2.7 Secondary PCR amplification cycling conditions for the Pfkelch13 gene 
 
Gene Denaturing 
Temperature 
Annealing 
Temperature 
Extension 
Temperature 
Pfkelch13 94°C for 30 seconds 60°C for 120 seconds 72°C for 120 seconds 
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Agarose Gel Electrophoresis 
The PCR products obtained from the secondary PCR reactions were analysed on a 
1% agarose gel (1gm agarose + 100ml 1X TBE buffer). A 1kb ladder supplied by 
(Invitrogen, USA) was used to confirm the PCR product obtained using AlphaImager 
HP supplied by (ProteinSimple, USA).  
 
2.5 DNA sequencing 
The amplified DNA product obtained after the secondary PCR was then PCR purified 
using QIAquick PCR Purification Kit (Qiagen, Germany). The sequencing reactions 
were carried out using Sanger Sequencing (SimpliSeqTM DNA Sequencing, 
Quintarabio, USA). Each sample was sequenced using 6 different primers supplied 
by (Eurofins Genomics, USA). The list of primers used for sequencing is provided in 
table 2.8.  The sequencing reactions were prepared in PCR tubes with 10μl of sample 
and 5μl of each primer/reaction. 
 
Table 2.8 List of primers used for sequencing of the Pfkelch13 gene 
 
Oligonucleotide Sequence 5’ – 3’ Tm (°C) 
K13 – 1 
 
CGGAGTGACCAAATCTGGGA 62.4 
Kelch13_2 for seq 
 
GATATGAGTGTATTAGATTCGAAC 
 
57.7 
Kelch13_3 for seq 
 
GATACTTATGAAAAGAAAATTATTG 
 
53.1 
Kelch13_4 for seq 
 
GAAAAAGAAAAATATTATCAAGAA 
 
50.9 
Kelch13_5 for seq 
 
CAACAATGCTGGCGTATGTGTACACC 
 
66.2 
Kelch13_6 for seq 
 
GATAATAAAATTTATGTCATTGGTGG 
 
56.7 
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The sequencing data obtained after sequencing was analyzed using the software 
MacVector.  
 
2.6 Statistical tests 
Laboratory and clinical finding for children in the different disease groups were 
compared using the chi-square test in case of categorical variables. When comparing 
two independent groups due to non-normality of the data Wilcoxon-Rank-Sum Test 
was performed and for more than two groups the Kruskal-Wallis Test was 
performed. We also transformed parasite density and parasite load levels to 
common logs (log to the base 10) for better graphical representation of the data. 
Kaplan – Meier Survival analysis was also performed for parasite clearance times. 
All these statistical tests were performed using StataSE and the graphs were 
prepared using SAS (SAS Institute, USA).  
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RESULTS 
 
3.1 The study and baseline characteristics 
Between 2008 and 2013 a total of 269 children with CM, 232 children with SMA and 
213 community controls (CC) were enrolled. Of these we used 100 samples (50 high 
PfHrp2 and 50 low PfHrp2) from CM, 100 samples (50 high PfHrp2 and 50 low 
PfHrp2) from SMA and 75 children from the asymptomatic CC groups to isolate the 
genomic DNA from dried blood spots. We were unable to amplify the Pfkelch13 gene 
from 18 samples from the CM, 15 from the SMA and 26 from the asymptomatic CC 
groups due to low concentration of genomic DNA and low quality DNA and were 
excluded from the analysis (Table 2.1, 2.2 and 2.3). There were 4 ineligible samples 
in the CM group, and 6 ineligible samples in the SMA group due to the lack of follow-
up data, which were excluded from the analysis. In total we were able to amplify and 
genotype the Pfkelch13 gene in 78 samples from CM, 79 from SMA and 49 from 
asymptomatic (CC) groups (Figure 2.1).  
 
Children with SMA were younger than both children with CM and CC (P=0.0014; 
Table 3.1). The peripheral blood density of parasites was the highest in children 
with CM as compared to SMA (P=0.0356). Community children had negligible levels 
of parasitemia in peripheral blood as detected by microscopy (Table 3.1). Previously 
it has been documented that children with severe malaria generally have higher 
levels of parasite biomass due to potential sequestration of the parasite within the 
vasculature, which may not be adequately represented using the measurements of 
the parasite levels in the peripheral blood [67]. So, we also measured the 
concentration of PfHRP2, which gives an estimate of the overall parasite biomass. 
The parasite biomass (PfHRP2 concentration) differed among all the groups, with 
the highest concentration occurring in children with SMA (CM vs SMA vs CC) (P< 
0.0001; Table 3.1). Children with CM and SMA did not show any difference in the 
parasite clearance times (Table 3.1). Deaths caused by malaria were only observed 
in children with CM.  
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Table 3.1 Characteristics of children with cerebral malaria (CM), severe malarial anemia 
(SMA) and asymptomatic community children (CC) 
 Cerebral 
Malaria 
(CM, n=78) 
Severe 
Malarial 
Anemia 
(SMA, n=79) 
 
Community 
Children 
(CC, n=49) 
Pa 
Age (months), median (IQR) 
 
 
41.8 
(30.0 – 58.0) 
 
33.3 
(23.4 – 53.9) 
48.0 
(34.3 – 61.2) 
0.0018b 
Sex, male n (%) 
 
51(65) 
 
53(67) 25 (50) 0.154 
P. falciparum peripheral blood 
density (parasites/μl), median 
(IQR)  
 
53680 
(16200 – 
279240) 
(n =75) 
 
36820 
(4360 – 
117880) 
 
0 
(0 – 1240) 
(n =48) 
<0.0001c 
Total Parasite Biomass 
(PfHrp2)(ng/ml), Median 
(IQR) 
 
1825.2  
(309.6 – 
7486.5) 
 
2469.6  
(140.0 – 
3725.7) 
(n =78) 
4.8 
(4.8- 73.2) 
(n =44) 
<0.0001c 
Parasite clearance time 
(hours), median (IQR) 
 
48 
(24 – 72) 
(n =58) 
 
48 
(24 – 72) 
(n =66) 
NA 0.8590 
Prior Artemisinin Exposure, n  
(%) 
 
15 (20) 
(n =76) 
 
9 (13) 
(n =68) 
NA 0.296 
Death, n (%) 
 
15 (19) 
 
0 (0) 
 
NA 
 
<0.0001 
Mutants, n (%) 
 
46 (59) 
 
44 (56) 
 
27 (55) 
 
0.884 
 
a  Due to non-normality Kruskal – Wallis Test was performed when comparing three groups and 
Wilcoxon Rank-Sum Test when comparing two groups. Chi-squared test was used for categorical 
variables.  
b  All the pairs of groups differ significantly, except between CM and SMA (however close to 
significance). 
c  All the pairs of groups differ significantly. 
Abbreviations: PfHrp2 (Plasmodium falciparum Histidine Rich Protein -2); IQR (Interquartile 
Range); n (Number); NA (Not Applicable) 
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3.2 Detection of PfKelch13 gene mutations 
Whole gene sequencing was done on a total of 205 enrollment samples. 157 samples 
(78.5%) were from children with severe malaria and forty-eight samples (64%) 
were from children with an asymptomatic parasite infection (CC). 
Ninety children (57%) with severe malaria had non-synonymous mutations in the 
kelck13 gene; all the polymorphisms are shown in Table 3.2. One infection showed 
the presence of two kelch13 mutations upstream of the propeller region of the 
Pfkelch13 gene. 
 
The A578S mutation in the propeller region of the Pfkelch13 gene was identified in a 
single infection. A578 has been previously observed in Africa and Asia, and in some 
clinical cases has been associated with delayed clearance [50, 52, 68, 69]. We did not 
observe any of the mutations observed in SEA which have been associated with in-
vitro delayed parasite clearance times.   
 
 
Table 3.2 Nonsynonymous mutations observed in the Pfkelch13 gene in 157 children 
with severe malaria (CM and SMA) 
Polymorphisms Reference 
Sequence (3D7) 
Mutant Sequencea No. of isolates/Total 
isolates (%) 
G112E GGA GAA 1 (0.6) 
N132S AAT AGT 2 (1.3) 
142Nb  AAT 4 (2.5) 
142NNb  AAT AAT 41 (26) 
N142D AAT GAT 2 (1.3) 
K189N AAA AAT 3 (1.9) 
K189T AAA ACA 26 (16.5) 
R255K AGA AAA 7 (4.5) 
L258M TTG ATG 3 (1.9) 
K189T & Q271H AAT & CAG ACA & CAT 1 (0.6) 
A578S GCT TCT 1 (0.6) 
a  Mutated bases are in bold and underlined. 
b  Insertion. 
G:Glycine, E:Glutamic acid, N:Asparagine, S:Serine, D:Aspartic acid, K:Lysine, 
T:Threonine,R:Argenine, L:Leucine, M:Metheonine, Q:Glutamine, H:Histidine, A:Alanine 
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There were also synonymous mutations in the Pfkelch13 gene (4%) in children with 
severe malaria (CM and SMA). Three of these infections were associated with a 
synonymous and a nonsynonymous mutation. A list of these synonymous mutations 
is provided in (Table 3.3). 
 
 
Table 3.3 Synonymous and nonsynonymous mutations observed in the Pfkelch13 gene 
in 157 children with severe malaria (CM and SMA) 
Polymorphisms Reference Sequence 
(3D7) 
Mutant Sequencea No. of isolates/Total 
isolates (%) 
K189T & L251L AAA & CTA ACA & CTG 1 (0.6) 
K189T & V219V AAA & GTA ACA & GTT 1 (0.6) 
K189N & L119L AAA & TTG AAT & CTG 1 (0.6) 
G220G GGT GGC 1 (0.6) 
T474T ACA ACC 1 (0.6) 
G496G GGT GGG 1 (0.6) 
a  Synonymous mutated bases are italicized and nonsynonymous mutated bases are in bold and 
underlined. 
K:Lysine, T:Threonine, V:Valine, G:Glycine 
 
 
Nonsynonymous mutations were observed in 54% of community control children 
who were asymptomatic infected with malaria. Most of the nonsynonymous 
mutations (50%) were observed upstream of the propeller regions of the Pfkelch13 
gene. There were two CC children with parasite mutations in the propeller region of 
the Pfkelch13 gene. One infection had the A578S, which was also observed in an 
infection associated with the severe malaria group, and the other infection had a 
serine residue replaced at position 522 by a cysteine (S522C). The S522C mutation 
has also been previously observed in Africa [70, 71]. All the nonsynonymous 
mutations are provided in Table 3.4. There were no synonymous mutations 
associated with asymptomatically infected CC children.  
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Table 3.4 Nonsynonymous mutations observed in the Pfkelch13 gene in 49 
asymptomatic community control (CC) children 
Polymorphisms Reference Sequence 
(3D7) 
Mutant Sequencea No. of isolates/Total 
isolates (%) 
G112E GGA GAA 1 (2) 
142Nb  AAT 1 (2) 
142NNb  AAT AAT 16 (33) 
K189T AAA ACA 6 (12.5) 
N197D AAT GAT 1 (2) 
S522C AGT TGT 1 (2) 
A578S GCT TCT 1 (2) 
a Mutated bases are in bold and underlined 
b Insertions 
G:Glycine, E:Glutamic acid, N:Asparagine, K:Lysine, T:Threonine, S:Serine, C:Cysteine, A:Alanine 
 
 
3.3 Frequency distribution of Pfkelch13 alleles in CM, SMA and CC children 
We observed malarial infections in CM, SMA and asymptomatic CC children with 
mutations in the Pfkelch13 gene. The two most prevalent forms of mutations were 
lysine residue replaced at position 189 by a threonine (K189T) (n=32) and at 
position 142 double insertion of arginine residue (142NN) (n=57) insertion. In 
children with CM, 20% of the infections had the K189T (n=16) mutation and the 
142NN (n=16) insertion each (Figure 3.1A). Children with SMA had 13% of the 
infections with K189T (n=10) mutations and 32% with the 142NN (n=25) insertion 
(Figure 3.1B, Table 3.5). Similarly, in CC children the prevalence of K189T mutation 
was 13% (n=6) and 33% for the 142NN (n=16) insertion (Figure 3.1C). The A578S 
mutation in the propeller region of the Pfklech13 gene was identified in one child 
belonging to SMA and asymptomatic CC groups each. The S522C mutation was 
identified solely in one kid with an asymptomatic infection in the CC group. 
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Table 3.5 Distribution of K189T, 142NN and wild-type strains in children with CM, SMA 
and asymptomatic community control (CC) 
 K189T 142NN Wild-Type Pa 
Cerebral Malaria (CM), 
n (%) 
 
16 (20) 16 (20) 32 (41)  
 
 
0.368 Severe Malarial 
Anemia (SMA), n (%) 
 
10 (13) 25 (32) 35 (44) 
Asymptomatic 
Controls (CC), n (%) 
6 (12) 16 (33) 22 (45) 
a Chi-squared test was used for categorical variables 
 
 
 
 
      A 
 
     Figure 3.1.A Percentage distribution of Pfkelch13 alleles in CM (Cerebral Malaria)                
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Figure 3.1.B Percentage distribution of Pfkelch13 alleles in SMA (Severe Malarial 
Anemia) 
 
        Figure 3.1.C Percentage distribution of Pfkelch13 alleles in CC (Community  
        Children) 
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3.4 Differences in the characteristics of children infected with different 
Pfkelch13 mutants in severe malaria (CM and SMA). 
The distributions of the most prevalent Pfkelch13 genotype (K189T, 142NN, other 
mutants and 3D7) among children with CM & SMA are shown in Table 3.5. In 
children with severe malaria parasites with the 142NN insertion compared to 3D7 
(wild-type) Pfkelch13 genotype had reduced parasite clearance times (median, 
interquartile range, in hours: 24, [24 – 48] vs 48, [48 – 72], P = 0.0001) upon quinine 
treatment (Table 3.6). Similarly, parasites with the K189T mutations when 
compared to the 3D7 Pfkelch13 genotype had reduced clearance time (median, 
interquartile range, in hours: 24, [24 – 48] vs 48, [48 – 72], P = 0.0258). However, 
there was no significant difference observed between the K189T and 142NN 
insertion groups (median, interquartile range, in hours: 24, [24 -48], P=0.4764). 
Further, there was no significant difference in parasite clearance times upon quinine 
treatment between the wild-type and other mutant groups (median, interquartile 
range, in hours: 48, [48 – 72], P = 0.7256).  
 
In children with severe malaria, parasites with the 142NN insertion also had lower 
parasite biomass when compared to 3D7 Pfkelch13 genotype (PfHRP2, ng/ml, 
median [IQR]; 370.8 [125.5 – 3463.2] vs 3134.4 [273.6 – 6842.4], P = 0.0307; Figure 
3.2A). Similarly, there was a difference in the parasite biomass between the 
participants with parasites having the 142NN insertion when compared to the 
K189T mutation groups (PfHRP2, ng/ml, median [IQR]; 370.8 [125.5 – 3463.2] vs 
3134.4 [600 – 6684.2], P = 0.0182). Severe malaria infections with 142NN insertion 
had lower peripheral parasite density when compared to 3D7 Pfkelch13 genotype 
(median [IQR], 23110 parasites/μl [2000 – 65820] vs 55350 parasites/μl [12300 – 
224600], P = 0.0207; Figure 3.2B). Equally, there was a difference in the parasite 
density between the infections having the 142NN insertion and K189T mutation 
groups (median [IQR], 23110 parasites/μl [2000 – 65820] vs 46920 parasites/μl 
[20060 – 107820], P = 0.0445). 
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Table 3.6 Characteristics of children with K189T, 142NN, Other Mutants, Wild-Type 
(3D7) in children with severe malarial infection 
 K189T 
(n =26) 
142NN 
(n =41) 
Other 
Mutants 
(n =23) 
Wild-Type 
(n =67) 
Pa 
Age (months), 
Median (IQR) 
 
 
35.9 
(23.0 -48.7) 
41.1 
(28.1 – 57.6) 
36.5 
(30.5 – 57.8) 
39.3 
(25.0 – 49.7) 
0.7755 
Sex (male), n (%) 
 
 
19(73) 33 (80) 14 (61) 38 (57) 0.064 
P. falciparum 
peripheral blood 
density 
(parasites/μl), 
median (IQR)  
 
 
46920 
(20060 – 
107820) 
(n =25) 
23110 (2000 
– 65820) 
(n =40) 
52800 
(3560 – 
328180) 
 
 
55350 
(12300 – 
224600) 
(n =66) 
0.0989b 
Total Parasite 
Load 
(PfHrp2)(ng/ml), 
Median (IQR) 
 
 
3134.4 (600 – 
6684.2) 
370.8 (125.5 
– 3463.2) 
(n =40) 
 
664.9 
(160.8 – 
5206.9) 
3134.4 
(273.6 – 
6842.4) 
 
0.0703b 
Parasite 
clearance time 
(hours), median 
(IQR) 
 
 
24 
(24 – 48) 
(n =19) 
24 
(24 – 48) 
(n =37) 
48 
(48 – 72) 
(n =17) 
48 
(48 – 72) 
(n =51) 
0.0003c 
Prior Artemisinin 
exposure, n (%) 
 
 
1 (5) 
(n =22) 
7 (18) 
(n =39) 
 
4(18) 
(n =22) 
12(20) 
(n =61) 
0.422 
Deaths, n (%) 
 
 
4(15) 
 
1(2) 
 
4(17) 
 
6(9) 0.166 
a  Kruskal – Wallis Test was performed. Chi-squared test was used for categorical variables. 
b  For differences between groups having a P<0.10, we performed exploratory post-hoc analysis. 
c  Log-rank Test for equality of survivor functions was performed between the groups. Children 
who died were censored. 
Abbreviations: PfHrp2 (Plasmodium falciparum Histidine Rich Protein -2); IQR (Interquartile 
Range); n (Number). 
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3.5 Frequency distribution of parasite clearance times in children with severe 
malaria (CM and SMA) 
57.89% of the children with an infection (CM and SMA) harboring the K189T 
mutation in the Pfkelch13 gene cleared the parasites within 24 hours (Figure 3.3A 
and Figure 3.3B). Similarly children infected with the parasite carrying the 142NN 
insertion (64.86%) in the Pfkelch13 gene also cleared the parasite in 24 hours 
(Figure 3.3A and Figure 3.3B). In contrast only 29.41% of the infections with the 
wild-type (3D7 strain) for the Pfkelch13 gene cleared in 24 hours (Figure 3.3A and 
Figure 3.3B), while 47.06% of the infection took 72-96 hours to clear. All the other 
mutations identified on the Pfkelch13 gene were grouped together and only 29.41% 
of them cleared the parasite in 24 hours. The clearance times for the other mutants 
are shown in Appendix 1 (Figure 4.1). 
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        Figure 3.2.A Difference in the parasite biomass in children with severe malaria 
        Differences in the parasite biomass (PfHRP2) (transformed log to the  
        base 10 in children with severe malaria between 142NN and wild-type (p=0.0307); 
        and between K189T and 142NN  
       Figure 3.2.B Difference in the parasite density in children with severe malaria 
       Difference in the parasite density (transformed log to the base10) in    children with    
       severe malaria between 142NN and wild-type(p=0.0207); and  
       between K189T and 142NN 
       Other: K189N, N142D, L258M, R255K, 142N insertion, N132S, A578S,  
                   K189T & Q271H  
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        Figure 3.3.A Differences in the frequency of parasite clearance times between  
       infections with K189T, 142NN, Other mutations and wild-type  
       Other: K189N, N142D, L258M, R255K, 142N insertion, N132S, A578S, K189T & Q271H  
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Figure 3.3.B Kaplan-Meier survival analysis of different types of mutations 
Parasite clearance times for infections with different types of mutations: K189T, 
142NN, other mutations and wild-type. More than 50% of the infections with the 
K189T and 142NN mutations cleared within 24 hours. Some infections with other 
mutations cleared parasites in >96 hours. 
The log – rank test for equality of survivor functions between the groups was 
significant with a p value of 0.0003. The children who died were censored during 
the analysis.  
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DISCUSSION 
 
Most studies have looked at mutations in the Pfkelch13 associated with delayed 
parasite clearance upon artemisinin treatment. In the CMR01 study conducted 
between 2008 and 2013 in Uganda, children with severe malaria were treated with 
quinine upon enrollment. In this preliminary study conducted to investigate the 
prevalence of Pfkelch13 mutations in the CMR01 study. Treatment of malaria using 
artemisinin and its derivatives has led to the emergence of P. falciparum mutants 
with delayed clearance times in SEA. Parasite strains showing delayed clearance 
times correlated with in vitro assays after artemisinin treatment [72]. Study 
conducted by Hawkes et al, found that the presence of the mutation A578S in the 
Pfkelch13 gene was associate with delayed parasite clearance (>72hours) in 
children with severe malaria treated with artesunate: the three children with 
delayed parasite clearance times all had the A578S mutation [52]. This A578S 
mutation has previously been observed in P. falciparum malaria in Ethiopia and 
Bangladesh, but has not been associated with prolonged parasite clearance time 
with ACT treatment [50, 69]. In our study we found only a single infection had the 
presence of A578S mutation in the severe malaria group and had a parasite 
clearance time of 72 hours upon quinine treatment. A recent research study 
assessing mutant parasites with the A578S mutation showed that these mutants did 
not confer in vitro resistance to artesunate [71]. Our study could not test for 
resistance to artesunate since the children were treated with quinine. The 
mutations A578S was present at low frequency (2/206 infections). Future studies 
will need to determine if the A578S mutation is present more frequently in children 
who are treated with artesunate for severe malaria, and if there is any evidence in 
these cohorts to support the association between A578S and delayed parasite 
clearance time. 
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Our sequencing results of the Pfkelch13 gene did not provide any evidence of 
mutations associated with delayed parasite clearance in SEA [49, 50, 57, 60, 73] 
suggesting that the mutations previously associated with delayed parasite clearance 
in Asia have not become prevalent in our study area. This could be due to the recent 
introduction of ACTs as a drug to treat P. falciparum related malaria in Africa. 
Furthermore, among our asymptomatic community controls we found two children 
with infections carrying the A578S and S522C mutation each. The S522C mutation 
has been previously reported in Uganda [74] however; in vitro studies have not 
been conducted using these mutants.  
 
Studies conducted in SEA where ACTs have been used to treat malarial infections 
since the 1990s and were the first to report cases of delayed parasite clearance [38]. 
Delayed parasite clearance to artemisinin treatment was associated with mutation 
in the propeller domain of the Pfkelch13 gene [49]. Furthermore, studies observed 
that mutations in the propeller domain of the Pfkelch13 gene were associated with 
delayed parasite clearance, while mutations upstream of the propeller domain may 
not have a role in delayed parasite clearance times with artemisinin treatment [50].  
 
The two most prevalent mutations were the K189T and the 142NN insertion in our 
cohort. These mutations have been identified previously in Bangladesh and Senegal 
[74, 75] where malarial infections were being treated with ACTs. These mutations 
were, however, not associated with delayed parasite clearance upon treatment with 
ACTs. In our study we found the children infected with the mutant parasite having 
the 142NN insertion had lower parasite biomass and lower parasite density as 
compared to infections with wild-type parasite. Upon administration of quinine the 
infections with K189T mutants and 142NN insertion cleared faster (24 hours) as 
compared to infections with wild-type parasite (48 hours). This faster clearance 
suggests that these mutant parasites might be more sensitive to quinine compare to 
wild-type strains. The lower parasite density and parasite biomass in 142NN mutant 
infections could indicate a possible fitness cost associated with these parasites. To 
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the contrary this could also suggest higher virulence associated with these strains, 
despite low parasite burden and parasite density were able to cause severe malaria.  
These were very interesting and unexpected results. The role-played by these 
mutations in the Pfkelch13 gene and its association with quinine treatment have not 
been studied before.  
 
Genes like Pfmdr1, Pfnhe1 and Pfcrt that have been associated with efficacy of 
quinine treatment. In vitro studies conducted on strains of parasites with mutations 
in these genes that have shown reduced sensitivity to quinine treatment [44, 76-78]. 
Increased Pfmdr1 copy number has been associated with decrease in quinine 
sensitivity [76]. Previous reports from Uganda have found a modest association 
between mutations in the Pfmdr1 gene and quinine sensitivity [78]. The number of 
repeats in Pfnhe also determined the sensitivity to in vitro quinine treatment [77]. 
Other in vitro studies have also suggested mutations in the Pfcrt gene could also 
result in decreased quinine sensitivity [79].  Mutations in Pfkelch13 could be in 
linkage disequilibrium with mutations in other genes that could affect the parasite 
clearance times upon quinine treatment. 
 
Naturally acquired host immunity is another key factor to consider in parasite 
clearance times. Multiple infections eventually lead to a much better immune 
response to malaria infection, but do not lead to sterile immunity. Immunity to 
malaria parasite in individuals in regions of high transmission is more pronounced 
as compared to individuals from medium or low transmission areas. These factors 
could also contribute to faster parasite clearance times in our cohort. 
 
With the recent adoption of ACTs as the first line of treatment in most countries in 
Africa, surveillance of Pfkelch13 mutations is required to stymie the spread of 
mutant strains associated with delayed parasite clearance times with artemisinin. 
There have been few reports of mutations in the propeller domain of the Pfkelch13 
gene in Mali, Ethiopia and Uganda [52, 53, 55], however, in very low frequency. 
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Further investigation in the role played by other mutations in the Pfkelch13 gene 
using in vitro assays might provide evidence regarding parasite clearance times and 
use of ACTs in malarial treatment. Similarly, investigating other mutations in other 
genes might help in understanding the various proposed mechanism in delayed 
clearance to artemisinin treatment.  
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Appendix A 
 
 
 
 
 
 
          
         Figure 4.1 Dot-Plot with all the other mutants and their parasite clearance  
         times after quinine treatment 
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